Hennion & Walsh Asset Management, Inc. Immunovant, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$18.55 - $39.96 $524,000 - $1.13 Million	-28,248 Reduced 16.49%	143,080 $5.49 Million
Q2 2023 Aug 09, 2023	SELL	$14.2 - $23.75 $798,437 - $1.34 Million	-56,228 Reduced 24.71%	171,328 $3.25 Million
Q1 2023 Apr 20, 2023	SELL	$15.27 - $19.72 $398,241 - $514,297	-26,080 Reduced 10.28%	227,556 $3.53 Million
Q4 2022 Jan 12, 2023	BUY	$6.59 - $17.75 $157,902 - $425,307	23,961 Added 10.43%	253,636 $4.5 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $24,845 - $40,271	-6,322 Reduced 2.68%	229,675 $1.28 Million
Q2 2022 Jul 19, 2022	BUY	$3.38 - $5.65 $50,230 - $83,964	14,861 Added 6.72%	235,997 $920,000
Q1 2022 Apr 26, 2022	BUY	$5.06 - $8.77 $305,300 - $529,146	60,336 Added 37.52%	221,136 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $693,843 - $882,212	94,658 Added 143.11%	160,800 $1.37 Million
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $158,720 - $257,439	22,642 Added 52.05%	66,142 $575,000
Q2 2021 Aug 13, 2021	BUY	$9.4 - $16.85 $408,900 - $732,975	43,500 New	43,500 $460,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.